Search Results - jesus+campagna

9 Results

Sort By:

Interactive Systems and Methods for Identifying Target Proteins in Drug Discovery (Case No. 2025-098)

Summary: UCLA researchers from the Department of Electrical and Computer Engineering have developed a novel computational system for target protein identification, enabling integrative drug discovery. Background: Target identification (Target ID) in drug discovery involves the identification and evaluation of protein candidates that could interact...

Published: 10/1/2025 | Inventor(s): Xiang Chen, Youngseung Jeon, Christopher Hwang, Ziwen Li, Jesus Campagna, Varghese John, Whitaker Cohn, Eunice Jun

Keywords(s): AI-driven drug discovery, Alzheimer’s disease target discovery, Bioinformatics software platform, Drug, Drug Discovery, Functional annotation of proteins, High-throughput docking, large language models (LLMs), Ligand-protein docking, Mechanism-of-action prediction, Molecular docking simulation, Multi-criteria decision support, Neurodegenerative disease therapeutics, Pathway-centric drug targeting, personalized medicine, PPI-Comparator, PPI-Explorer, Protein structure prediction, Protein-protein interaction (PPI) analysis, Rational drug design, Retrieval-augmented generation (RAG), Semantic similarity modeling, Small molecule screening, Systems biology interface, Target identification (Target ID), Therapeutic impact modeling, User-guided AI exploration

Category(s): Software & Algorithms, Software & Algorithms > AI Algorithms, Software & Algorithms > Artificial Intelligence & Machine Learning, Software & Algorithms > Digital Health, Life Science Research Tools, Life Science Research Tools > Research Methods, Platforms, Platforms > Drug Delivery

Small molecule sAPPalpha enhancers that inhibit brain p-Tau as a therapeutic for Alzheimer’s Disease (UCLA Case No. 2025-163)

Contact UCLA Technology Development Group to learn more.

Published: 9/18/2025 | Inventor(s): Varghese John, Dongwook Wi, Jesus Campagna

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

Novel MARK4 Inhibitors for Neurodegenerative Disorders (UCLA Case No. 2021-321)

UCLA researchers in the Department of Neurology have developed highly selective inhibitors of MARK4, aiming to revolutionize the treatment landscape for cancer and neurodegenerative disease through precise molecular targeting. BACKGROUND: MARK4 (Microtubule Affinity-Regulating Kinase 4) is a serine/threonine kinase from the AMP-activated protein...

Published: 9/10/2025 | Inventor(s): Varghese John, Jason Hinman, Jesus Campagna

Keywords(s):

Category(s): Therapeutics > CNS and Neurology

2021-241: Enhancers of Brain Gamma Oscillations for Treatment of Neurological Disorders

SUMMARY: UCLA researchers in the Department of Neurology have developed a novel small molecule to improve native gamma oscillations as a treatment for cognitive decline in various neurological disorders. BACKGROUND: Neural circuits are facilitated by brain oscillations or rhythmic electric activity at distinct frequencies. These frequency variations...

Published: 7/17/2025 | Inventor(s): Varghese John, Istvan Mody, Jesus Campagna, Barbara Jagodzinska, Xiaofei Wei

Keywords(s):

Category(s): Therapeutics > CNS and Neurology, Therapeutics > Psychiatry And Mental Health

Novel Compounds Targeting APOE4 That Enhance Brain SIRT1 Levels and Target Novel Mechanism of Action (UCLA Cases 2020-832, 2025-277)

Researchers at UCLA's Drug Discovery Lab and Department of Chemistry have developed new chemical entity (NCE) analogs of A03, which together form a new class of compounds that target apolipoprotein E4 (ApoE4)-mediated deficits in the tau deacetylase enzyme, sirtuin 1 (SirT1). These NCEs provide an opportunity for novel therapeutic development in Alzheimer's...

Published: 9/18/2025 | Inventor(s): Varghese John, Jesus Campagna, Michael Jung

Keywords(s): Brain

Category(s): Therapeutics

2018-200 AMYLOID PRECURSOR PROTEIN-SELECTIVE BACE INHIBITORS (ASBIS) FOR ALZHEIMER’S DISEASE

Amyloid Precursor Protein-Selective BACE Inhibitors for Alzheimer’s DiseaseSUMMARYUCLA researchers in the Department of Neurology have invented novel Alzheimer’s disease (AD) therapeutics that are selective for BACE1 inhibition and cleavage of the amyloid precursor protein (APP) substrate.BACKGROUNDAlzheimer’s disease is characterized...

Published: 7/17/2025 | Inventor(s): Barbara Jagodzinska, Varghese John, Patricia Spilman, Jesus Campagna

Keywords(s): Cns, Life Science Research Tools, Medical Devices and Materials, Targets And Assays, Therapeutics & Vaccines

Category(s): Life Science Research Tools, Diagnostic Markers > Targets And Assays, Medical Devices, Therapeutics, Therapeutics > CNS and Neurology

New 3D-Exoquant Method for the Analysis of Surface Molecules and Quantification of Tissue-Specific Exosomes in Biological Fluids (UCLA Case No. 2016-305, 2016-731)

SUMMARYUCLA researchers in the Department of Neurology have developed a novel high sensitivity exosome and extracellular vesicle disease detection technology for use in the clinical and research setting. BACKGROUNDDetection of surface biomarkers located on extracellular bodies, such as vesicles and exosomes is of great clinical and research significance...

Published: 9/24/2025 | Inventor(s): Varghese John, Patricia Spilman, Jesus Campagna, Peter Heinzelman, Tina Bilousova

Keywords(s): Diagnostic Markers & Platforms, Diagnostic Platform Technologies (E.G. Microfluidics)

Category(s): Diagnostic Markers, Platforms > Diagnostic Platform Technologies

2017-772 ALLOSTERIC BACE INHIBITORS FOR TREATMENT OF ALZHEIMER’S DISEASE

Allosteric BACE Inhibitors For Treatment Of Alzheimer’s DiseaseSUMMARYUCLA researchers from the Department of Neurology have discovered a new class of drug candidates for Alzheimer’s disease. These small molecule compounds can specifically inhibit target enzymes to prevent target protein cleavage through an allosteric mechanism, preventing...

Published: 7/17/2025 | Inventor(s): Varghese John, Barbara Jagodzinska, Patricia Spilman, Jesus Campagna, Kanagasabai Vadivel, Michael Jung

Keywords(s): Cns, Therapeutics & Vaccines

Category(s): Therapeutics, Therapeutics > CNS and Neurology

2014-864 ApoE4-Targeted Therapeutics that Increase SIRT1

ApoE4-Targeted Theraputics That Increase SIRT1SUMMARYUCLA researchers have identified Alaproclate (A03) as a promising drug candidate to treat Mild Cognition Impairment (MCI) and Alzheimer’s disease (AD) through inhibition of the ApoE4 neurotoxicity.BACKGROUNDAlzheimer’s disease (AD) is a neurodegenerative disease whose cause is largely...

Published: 7/17/2025 | Inventor(s): Michael Jung, Varghese John, Dale Bredesen, Barbara Jagodzinska, Jesus Campagna, Rammohan Rao, Johnny Pham

Keywords(s):

Category(s): Therapeutics, Therapeutics > CNS and Neurology